Intravenous immunoglobulin therapy – which essentially consists on pooled antibodies from a thousand or more blood donors – could be a promising way of treating MPO-positive ANCA-associated vasculitis patients, an early study suggests.
In a rat model of the disease, this therapy lowered the number of anti-MPO antibodies, reduced neutrophil traps – web-like structures of DNA produced by activated neutrophils – and suppressed the development of vasculitic lesions, the researchers found.
ANCA-associated vasculitis, an autoimmune disease, is caused by the production of autoantibodies — antibodies that wrongly target and attack healthy cells — leading to blood vessel inflammation and swelling in affected tissues and organs.
Specifically, these autoantibodies target immune cells called neutrophils, attacking one of two proteins at their surface: proteinase 3 (PR3) or myeloperoxidase (MPO).
Intravenous immunoglobulins, a treatment where antibodies (immunoglobulins) from healthy donors are injected into patients with immune disorders, has been proven useful against autoimmune diseases, including in ANCA-associated vasculitis.
Indeed, its’ know to effectively treat peripheral neuropathy in people with eosinophilic granulomatosis with polyangiitis (EGPA), where ANCAs target the MPO protein. But how it works here — its mechanism of action — is not clear.
Researchers in Japan investigated how intravenous immunoglobulins affect the progression of MPO-positive vasculitis by studying neutrophils cultured in the lab and a rat model for the disease.
They noted that neutrophils treated with intravenous immunoglobulins produced fewer neutrophil traps. These traps are web-like structures of DNA formed by neutrophils; the structures capture and kill different microorganisms to protect the body. In excess, however their formation has been linked to progression in ANCA-associated vasculitis.
Experiments performed on rats showed that intravenous immunoglobulins regulated neutrophil trap formation, preventing its excess; lessened the amounts of anti-MPO antibodies produced, or autoantibodies; and prevented the formation of lesions in the small blood vessels.
“The collective findings indicated that [intravenous immunoglobulins] reduce [neutrophil trap] formation and ameliorates the development of MPO-[ANCA-associated vasculitis]. It is expected that future prospective clinical studies will prove the efficacy of [intravenous immunoglobulin] therapy as one therapeutic option for treating patients with MPO-[ANCA-associated vasculitis],” the researchers concluded.
Further studies should also determine the mechanism by which intravenous immunoglobulins control the formation of neutrophil traps, they suggested.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?